Seven-year Longitudinal Population Study of Change in Gamma-glutamyltransferase: The Tromsø Study

Nilssen, Odd; Førde, Olav Helge

doi:10.1093/oxfordjournals.aje.a117075

Cited by 89 publications

(54 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Possible explanations account for the positive correlation of longitudinal GGT change with an increase in CVD risk factors like body mass index, total serum cholesterol, high-density lipoprotein (HDL) cholesterol, and number of cigarettes per day in men. 35 This explanation is supported by our finding of a sex-specific positive association of GGT with CVD mortality. Although cause-specific estimates for risk of mortality from CVD showed much wider confidence intervals compared to all cause analysis, our findings suggest sex-specific interactions among CVD risk factors, GGT, and mortality.…”

Section: Discussionsupporting

confidence: 67%

Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels # †

et al. 2009

View full text Add to dashboard Cite

The aim of the present study was to investigate the association of serum gamma-glutamyltransferase (GGT) levels with all-cause mortality and to assess the impact of ultrasonographic findings of hepatic hyperechogenicity in that association. We used data from 4,160 subjects (2,044 men and 2,116 women) recruited for the population-based Study of Health in Pomerania (SHIP) without baseline hepatitis B and C infections or liver cirrhosis. GGT was divided into age-and sex-dependent quintiles to calculate overall and sex-specific crude incidence mortality rates. Hepatic steatosis was defined by elevated GGT levels (>80%) and the presence of hyperechogenic liver ultrasound. We used multiple-adjusted Cox proportional hazards regression models, first, to assess the direct effect of GGT on all-cause mortality, second, to stratify according to the ultrasonographic finding, and third, to investigate potential mediating effects of cardiometabolic risk factors. During 29,810 person-years (7.3 years, median) of follow-up, 307 individuals (7.5%) died, resulting in a death rate of 0.86 deaths per 1000 person-years. Elevated GGT levels were associated with increased risk of mortality in men (hazard ratio [HR] 1.49; 95% confidence interval [CI], 1.08-2.05), but not in women (HR 1.30; 95% CI, 0.80-2.12). This association was even stronger in men with hepatic steatosis (HR 1.98; 95% CI, 1.21-3.27). Cause-specific mortality analysis by cardiovascular disease deaths confirmed the sex-specific association. Adjustment for cardiometabolic risk factors did not affect the estimates. Conclusion: In the case of increased GGT levels, liver ultrasound should be performed, not only for diagnosis, but also for further risk stratification.

show abstract

Section: Discussionsupporting

confidence: 67%

Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels # †

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Serum GGT is associated with hypertension, dyslipidemia, and abnormal glucose tolerance, suggesting that it is related to hepatic insulin resistance rather than non-alcoholic fatty liver disease (Ikai et al 1994;Nilssen and Førde 1994;Kang et al 2007). GGT plays a direct role in the generation of reactive oxygen species in the presence of iron or other transition metals (Brown et al 1998), inducing lipid peroxidation in human biological membranes (Paolicchi et al 1997), and is an indirect marker of antioxidant systems, with the primary function of maintaining the intracellular concentration of glutathione in response to oxidative stress (Karp et al 2001).…”

Section: Discussionmentioning

confidence: 99%

Association between Serum Gamma-Glutamyl Transferase Level and Prehypertension among Community-Dwelling Men

Kawamoto

Kohara

Tabara

et al. 2008

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Serum gamma-glutamyl transferase (GGT) activity is a general clinical marker of excessive alcohol consumption, and GGT reflects changes in oxidative stress and implicated in the progression of hypertension. Recent guidelines classify persons with above-optimal blood pressure (BP) but not clinical hypertension as having prehypertension for a systolic BP (SBP) of 120 to 139 mmHg and/or a diastolic BP (DBP) of 80 to 89 mmHg; however, only limited data are available on the association between serum GGT and this entity among community-dwelling men in Japan. We performed a cross-sectional study to examine whether serum GGT was associated with prehypertension. Study participants (754 men, age 56 ± 15 years) without a clinical history of stroke, transient ischemic attack, myocardial infarction, angina, or renal failure were recruited from a single community. Thirty-seven percent of participants had prehypertension and 39.3% had hypertension. Multiple regression analysis using SBP and DBP as objective variables, adjusted for risk factors as explanatory variables, showed that log GGT was significantly and independently associated with elevated SBP (β = 0.109, P = 0.006) and DBP (β = 0.238, P < 0.001). Compared with participants in the lowest tertile of serum GGT (< 29 IU/L), the multivariate-adjusted odds ratio (OR) (95% CI) for prehypertension was 1.73 (1.06-2.81) for the middle tertile (29-53 IU/L) and 2.37 (1.31-4.31) for the highest tertile (> 53 IU/L). Moreover, the respective ORs for hypertension were 1.82 (1.04-3.18) and 3.11 (1.61-6.03). These results suggest that higher serum GGT levels are associated with prehypertension or hypertension in the general male population. gamma-glutamyl transferase; hypertension; prehypertension; risk factor; Japanese men. Tohoku

show abstract

“…In addition to the role in LDL oxidation during the atherosclerotic process, GGT activity is associated with other atherosclerotic risk factors including insulin resistance, 25 metabolic syndrome, 18,26 hypertension, 4 and diabetes. 5…”

Section: Importance Of Ggt Activity In Atherosclerosismentioning

confidence: 99%

The Importance of Gamma‐Glutamyltransferase Activity in Patients with Coronary Artery Disease

Demircan

Yazıcı

Durna

et al. 2009

Clinical Cardiology

View full text Add to dashboard Cite

Background: In this study, we sought to investigate the relation of gamma-glutamyltransferase (GGT) levels with the significance of coronary artery disease (CAD), clinical presentation, left ventricular (LV) function, and inflammatory activity. Methods: A total of 235 patients (mean age: 60.1 ± 10.5 years, 166 [70%] males) who had coronary angiography were included in the study. Patients who had CAD constituted the study group (Group 1, n = 189) and patients who had insignificant coronary disease or normal coronary activity constituted the control group (Group 2, n = 46). Results: GGT levels were higher in Group 1 than Group 2 (38.7 ± 30.9 U/L versus 27.5 ± 17.5 U/L, p = 0.025). Left ventricular ejection fraction (LVEF) was lower in Group 1 than Group 2 (52.6%±11.7% versus 58.8%±11.3%, p<0.002). GGT activity (40.2 ± 32.5 U/L versus 29.1 ± 18.3 U/L, p<0.002) and c-reactive protein (CRP) levels (33.9 ± 43.6 mg/dl versus 17.8 ± 29.8 mg/dl, p<0.002) were higher, LVEF (52.6%±12.1% versus 56.5%±11.0%, p = 0.021) was lower in patients with acute coronary syndrome compared with stable CAD group. In regression analysis, CRP levels (p<0.0001, odds ratio [OR] = 3.77, 95% confidence interval [CI] 0.10

show abstract

Seven-year Longitudinal Population Study of Change in Gamma-glutamyltransferase: The Tromsø Study

Cited by 89 publications

References 0 publications

Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels # †

Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels # †

Association between Serum Gamma-Glutamyl Transferase Level and Prehypertension among Community-Dwelling Men

The Importance of Gamma‐Glutamyltransferase Activity in Patients with Coronary Artery Disease

Contact Info

Product

Resources

About